Exosomal microRNAs: Potential Nanotherapeutic Targets for Diabetic Kidney Disease

References

• Zhao L , ZhangJ, LeiSet al. Combining glomerular basement membrane and tubular basement membrane assessment improves the prediction of diabetic end-stage renal disease. J. Diabetes13(7), 572–584 (2021).
   PubMedGoogle Scholar
• Sugita E , HayashiK, HishikawaA, ItohH. Epigenetic alterations in podocytes in diabetic nephropathy. Front. Pharmacol.12, 759299 (2021).
   PubMedGoogle Scholar
• Das F , BeraA, Ghosh-ChoudhuryNet al. High glucose-stimulated enhancer of zeste homolog-2 (EZH2) forces suppression of deptor to cause glomerular mesangial cell pathology. Cell. Signal.86, 110072 (2021).
   PubMedGoogle Scholar
• Vallon V , ThomsonSC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol.74, 351–375 (2012).
   PubMed Web of Science ®Google Scholar
• Vartak T , GodsonC, BrennanE. Therapeutic potential of pro-resolving mediators in diabetic kidney disease. Adv. Drug Deliv. Rev.178, 113965 (2021).
   PubMedGoogle Scholar
• Thethi T , KamiyamaM, KoboriH. The link between the renin–angiotensin–aldosterone system and renal injury in obesity and the metabolic syndrome. Curr. Hypertens. Rep.14(2), 160–169 (2012).
   PubMed Web of Science ®Google Scholar
• Magee C , GrieveDJ, WatsonCJ, BrazilDP. Diabetic nephropathy: a tangled web to unweave. Cardiovasc. Drugs Ther.31(5–6), 579–592 (2017).
   PubMed Web of Science ®Google Scholar
• Jung SW , MoonJY. The role of inflammation in diabetic kidney disease. Korean J. Int. Med.36(4), 753–766 (2021).
   PubMed Web of Science ®Google Scholar
• Samsu N . Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed. Res. Int.2021, 1497449 (2021).
   PubMed Web of Science ®Google Scholar
• Lassén E , DaehnIS. Molecular mechanisms in early diabetic kidney disease: glomerular endothelial cell dysfunction. Int. J. Mol. Sci.21(24), 9456 (2020).
   PubMed Web of Science ®Google Scholar
• Nishad R , TahaseenV, KavvuriRet al. Advanced-glycation end-products induce podocyte injury and contribute to proteinuria. Front. Med.8, 685447 (2021).
   Google Scholar
• Zhang PN , ZhouMQ, GuoJet al. Mitochondrial dysfunction and diabetic nephropathy: nontraditional therapeutic opportunities. J. Diabetes Res.2021, 1010268 (2021).
   PubMedGoogle Scholar
• Mostafa DK , KhedrMM, BarakatMK, AbdellatifAA, ElsharkawyAM. Autophagy blockade mechanistically links proton pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of metformin/enalapril. Life Sci.265, 118818 (2021).
   PubMedGoogle Scholar
• Kalluri R , LeBleuVS. The biology, function, and biomedical applications of exosomes. Science367(6478), eaau6977 (2020).
   PubMed Web of Science ®Google Scholar
• He X , KuangG, WuY, OuC. Emerging roles of exosomal miRNAs in diabetes mellitus. Clin. Transl. Med.11(6), e468 (2021).
   PubMedGoogle Scholar
• Colombo M , RaposoG, ThéryC. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Ann. Rev. Cell Dev. Biol.30, 255–289 (2014).
   PubMed Web of Science ®Google Scholar
• Noonin C , ThongboonkerdV. Exosome–inflammasome crosstalk and their roles in inflammatory responses. Theranostics11(9), 4436–4451 (2021).
   PubMed Web of Science ®Google Scholar
• Tafrihi M , HasheminasabE. miRNAs: biology, biogenesis, their web-based tools, and databases. Microrna8(1), 4–27 (2019).
   PubMedGoogle Scholar
• Zuo Y , ChenL, HeXet al. Atorvastatin regulates MALAT1/miR-200c/NRF2 activity to protect against podocyte pyroptosis induced by high glucose. Diabetes Metab. Syndr. Obes.14, 1631–1645 (2021).
   PubMed Web of Science ®Google Scholar
• He F , PengF, XiaXet al. miR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia57(8), 1726–1736 (2014).
   PubMed Web of Science ®Google Scholar
• Chen YQ , WangXX, YaoXMet al. MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency. Am. J. Nephrol.34(6), 549–559 (2011).
   PubMedGoogle Scholar
• Lu Y , LiuD, FengQ, LiuZ. Diabetic nephropathy: perspective on extracellular vesicles. Front. Immunol.11, 943 (2020).
   PubMedGoogle Scholar
• Mohan A , SinghRS, KumariMet al. Urinary exosomal microRNA-451-5p is a potential early biomarker of diabetic nephropathy in rats. PLOS ONE11(4), e0154055 (2016).
   PubMed Web of Science ®Google Scholar
• Kim H , BaeYU, JeonJSet al. The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. J. Transl. Med.17(1), 236 (2019).
   PubMedGoogle Scholar
• Xie Y , JiaY, XieCet al. Corrigendum to ‘Urinary exosomal microRNA profiling in incipient type 2 diabetic kidney disease’. J. Diabetes Res.2018, 5969714 (2018).
   PubMedGoogle Scholar
• Prabu P , RomeS, SathishkumarCet al. MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the ‘Asian Indian phenotype’. Diabetes Metab.45(3), 276–285 (2019).
   PubMedGoogle Scholar
• Wang H , WangJ, LiuT, LengY, YangW. Stem cell-derived exosomal microRNAs: potential therapies in diabetic kidney disease. Biomed. Pharmacother.164, 114961 (2023).
   PubMedGoogle Scholar
• Jin J , WangY, ZhaoLet al. Exosomal miRNA-215-5p derived from adipose-derived stem cells attenuates epithelial–mesenchymal transition of podocytes by inhibiting ZEB2. Biomed. Res. Int.2020, 2685305 (2020).
   PubMed Web of Science ®Google Scholar
• Hao Y , MiaoJ, LiuWet al. Mesenchymal stem cell-derived exosomes carry microRNA-125a to protect against diabetic nephropathy by targeting histone deacetylase 1 and downregulating endothelin-1. Diabetes Metab. Syndr. Obes.14, 1405–1418 (2021).
   PubMed Web of Science ®Google Scholar
• Duan Y , ChenB, ChenFet al. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte. J. Cell. Mol. Med.25(23), 10798–10813 (2019).
   PubMedGoogle Scholar
• Cai X , ZouF, XuanR, LaiX. Exosomes from mesenchymal stem cells expressing microribonucleic acid-125b inhibit the progression of diabetic nephropathy via the tumour necrosis factor receptor-associated factor 6/Akt axis. Endocr. J.68(7), 817–828 (2021).
   PubMedGoogle Scholar
• Akers JC , GondaD, KimR, CarterBS, ChenCC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neurooncol.113(1), 1–11 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang L , YuD. Exosomes in cancer development, metastasis, and immunity. Biochim. Biophys. Acta Rev. Cancer1871(2), 455–468 (2019).
   PubMed Web of Science ®Google Scholar
• Lin J , LiJ, HuangBet al. Exosomes: novel biomarkers for clinical diagnosis. Sci. World J.2015, 657086 (2015).
   Google Scholar
• Zhang H , FreitasD, KimHSet al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol.20(3), 332–343 (2018).
   PubMed Web of Science ®Google Scholar
• Bowers EC , HassaninAAI, RamosKS. In vitro models of exosome biology and toxicology: new frontiers in biomedical research. Toxicol. In Vitro64, 104462 (2020).
   PubMedGoogle Scholar
• Tkach M , ThéryC. Communication by extracellular vesicles: where we are and where we need to go. Cell164(6), 1226–1232 (2016).
   PubMed Web of Science ®Google Scholar
• Li S , WuY, DingFet al. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale12(19), 10854–10862 (2020).
   PubMed Web of Science ®Google Scholar
• Duan L , XuL, XuXet al. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale13(3), 1387–1397 (2021).
   PubMed Web of Science ®Google Scholar
• Meldolesi J . Exosomes and ectosomes in intercellular communication. Curr. Biol.28(8), R435–R444 (2018).
   PubMed Web of Science ®Google Scholar
• Merchant ML , RoodIM, DeegensJKJ, KleinJB. Isolation and characterization of urinary extracellular vesicles: implications for biomarker discovery. Nat. Rev. Nephrol.13(12), 731–749 (2017).
   PubMed Web of Science ®Google Scholar
• Lakhter AJ , PrattRE, MooreREet al. Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia61(5), 1124–1134 (2018).
   PubMed Web of Science ®Google Scholar
• Chang W , WangJ. Exosomes and their noncoding RNA cargo are emerging as new modulators for diabetes mellitus. Cells8(8), 853 (2019).
   PubMed Web of Science ®Google Scholar
• Gauthier BR , Cobo-VuilleumierN, López-NoriegaL. Roles of extracellular vesicles associated non-coding RNAs in diabetes mellitus. Front. Endocrinol.13, 1057407 (2022).
   PubMedGoogle Scholar
• Chaput N , ThéryC. Exosomes: immune properties and potential clinical implementations. Semin. Immunopathol.33(5), 419–440 (2011).
   PubMed Web of Science ®Google Scholar
• Cortez MA , Bueso-RamosC, FerdinJet al. MicroRNAs in body fluids – the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol.8(8), 467–477 (2011).
   PubMed Web of Science ®Google Scholar
• Valadi H , EkströmK, BossiosAet al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol.9(6), 654–659 (2007).
   PubMed Web of Science ®Google Scholar
• Guay C , RegazziR. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat. Rev. Endocrinol.9(9), 513–521 (2013).
   PubMed Web of Science ®Google Scholar
• Karolina DS , TavintharanS, ArmugamAet al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab.97(12), E2271–E2276 (2012).
   PubMed Web of Science ®Google Scholar
• Eissa S , MatboliM, BekhetMM. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis. Biomed. Pharmacother.83, 92–99 (2016).
   PubMedGoogle Scholar
• Jia Y , GuanM, ZhengZet al. miRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy. J. Diabetes Res.2016, 7932765 (2016).
   PubMedGoogle Scholar
• Park S , LeeK, ParkIBet al. The profiles of microRNAs from urinary extracellular vesicles (EVs) prepared by various isolation methods and their correlation with serum EV microRNAs. Diabetes Res. Clin. Pract.160, 108010 (2020).
   PubMedGoogle Scholar
• Zhang W , ZhouX, ZhangHet al. Extracellular vesicles in diagnosis and therapy of kidney diseases. Am. J. Physiol. Renal Physiol.311(5), F844–F851 (2016).
   PubMed Web of Science ®Google Scholar
• Delić D , EiseleC, SchmidRet al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. PLOS ONE11(3), e0150154 (2016).
   PubMed Web of Science ®Google Scholar
• Florijn BW , DuijsJ, LevelsJHet al. Diabetic nephropathy alters the distribution of circulating angiogenic microRNAs among extracellular vesicles, HDL, and Ago-2. Diabetes68(12), 2287–2300 (2019).
   PubMed Web of Science ®Google Scholar
• Uil M , HauCM, AhdiMet al. Cellular origin and microRNA profiles of circulating extracellular vesicles in different stages of diabetic nephropathy. Clin. Kidney J.14(1), 358–365 (2021).
   PubMed Web of Science ®Google Scholar
• Su H , QiaoJ, HuJet al. Podocyte-derived extracellular vesicles mediate renal proximal tubule cells dedifferentiation via microRNA-221 in diabetic nephropathy. Mol. Cell. Endocrinol.518, 111034 (2020).
   PubMed Web of Science ®Google Scholar
• Jin J , ShiY, GongJet al. Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte. Stem Cell Res. Ther.10(1), 95 (2019).
   PubMed Web of Science ®Google Scholar
• Rayego-Mateos S , Morgado-PascualJL, Opazo-RíosLet al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int. J. Mol. Sci.21(11), 3798 (2020).
   PubMed Web of Science ®Google Scholar
• Ding X , JingN, ShenAet al. miR-21-5p in macrophage-derived extracellular vesicles affects podocyte pyroptosis in diabetic nephropathy by regulating A20. J. Endocrinol. Invest.44(6), 1175–1184 (2021).
   PubMed Web of Science ®Google Scholar
• Lee SE , JangJE, KimHSet al. Mesenchymal stem cells prevent the progression of diabetic nephropathy by improving mitochondrial function in tubular epithelial cells. Exp. Mol. Med.51(7), 1–14 (2019).
   Google Scholar
• Duan Y , LuoQ, WangYet al. Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLR4 and protect against diabetic nephropathy. J. Biol. Chem.295(37), 12868–12884 (2020).
   PubMed Web of Science ®Google Scholar
• Lv J , HaoYN, WangXP, LuWH, XieLY, NiuD. Bone marrow mesenchymal stem cell-derived exosomal miR-30e-5p ameliorates high-glucose induced renal proximal tubular cell pyroptosis by inhibiting ELAVL1. Ren. Fail.45(1), 2177082 (2023).
   PubMed Web of Science ®Google Scholar
• Gao C , WangB, ChenQet al. Serum exosomes from diabetic kidney disease patients promote pyroptosis and oxidative stress through the miR-4449/HIC1 pathway. Nutr. Diabetes11(1), 33 (2021).
   PubMed Web of Science ®Google Scholar
• Huang Y , LiR, ZhangLet al. Extracellular vesicles from high glucose-treated podocytes induce apoptosis of proximal tubular epithelial cells. Front. Physiol.11, 579296 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang S , WuJ, ZhuXet al. A novel approach to identify the mechanism of miR-145-5p toxicity to podocytes based on the essential genes targeting analysis. Mol. Ther. Nucl. Acids26, 749–759 (2021).
   Google Scholar
• Tsai Y , KuoM, HungWet al. High glucose induces mesangial cell apoptosis through miR-15b-5p and promotes diabetic nephropathy by extracellular vesicle delivery. Mol. Ther.28(3), 963–974 (2020).
   PubMed Web of Science ®Google Scholar
• Jiang ZZ , LiuYM, NiuXet al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell. Res. Ther.7, 24 (2016).
   PubMed Web of Science ®Google Scholar
• Nagaishi K , MizueY, ChikenjiTet al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci. Rep.6, 34842 (2016).
   PubMed Web of Science ®Google Scholar
• Liu T , JinQ, YangLet al. Regulation of autophagy by natural polyphenols in the treatment of diabetic kidney disease: therapeutic potential and mechanism. Front. Endocrinol.14, 1142276 (2023).
   PubMed Web of Science ®Google Scholar
• Shapouri-Moghaddam A , MohammadianS, VaziniHet al. Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol.233(9), 6425–6440 (2018).
   PubMed Web of Science ®Google Scholar
• Huang H , LiuH, TangJet al. M2 macrophage-derived exosomal miR-25-3p improves high glucose-induced podocytes injury through activation autophagy via inhibiting DUSP1 expression. IUBMB Life72(12), 2651–2662 (2020).
   PubMed Web of Science ®Google Scholar
• Hu R , LiX, PengCet al. miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes. BMJ Open Diabetes Res. Care8(1), e001101 (2020).
   PubMed Web of Science ®Google Scholar
• Jin J , QianF, ZhengDet al. Mesenchymal stem cells attenuate renal fibrosis via exosomes-mediated delivery of microRNA let-7i-5p antagomir. Int. J. Nanomed.16, 3565–3578 (2021).
   PubMed Web of Science ®Google Scholar
• Liu D , LiuF, LiZet al. HNRNPA1-mediated exosomal sorting of miR-483-5p out of renal tubular epithelial cells promotes the progression of diabetic nephropathy-induced renal interstitial fibrosis. Cell Death Dis.12(3), 255 (2021).
   PubMed Web of Science ®Google Scholar
• Zhong L , LiaoG, WangXet al. Mesenchymal stem cells-microvesicle-miR-451a ameliorate early diabetic kidney injury by negative regulation of P15 and P19. Exp. Biol. Med.243(15–16), 1233–1242 (2018).
   Web of Science ®Google Scholar